Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 21, 2025—Pramana and ARUP Laboratories announced a collaboration to digitize pathology slides and develop AI-powered algorithms to improve the assessment of bone marrow biopsies and address other diagnostic challenges in hematopathology.
March 20, 2025—Advanced Instruments, a subsidiary of Patricia Industries, announced the execution of a definitive agreement to acquire Nova Biomedical.
March 19, 2025—Northwestern Medicine and Vitestro announced a multiyear collaboration to advance automation in phlebotomy.
Pathology plays a critical role in cancer care, encompassing the development of new treatments, diagnosis, staging, grading of disease, and clinical decision-making. While histopathological slides of tissue biopsies using hematoxylin and eosin staining and immunohistochemical staining remain central to this process, the rise of precision medicine testing is placing greater demands on pathology labs. Health care organizations globally are grappling with ways to address these challenges, mainly due to the declining number of individuals choosing pathology as a specialty.
Webinar presenters Gwen Clarke, MD, FRCPC, Hematopathology and Transfusion Medicine, Island Health, Victoria British Columbia Canada, and Clinical Professor, Department of Laboratory Medicine Pathology, University of Alberta, and Nancy Robitaille, MD, FRCPC, Vice-President, Transfusion Medicine, Héma-Québec, Montreal Canada Hematology-Oncology, CHU Sainte-Justine, Montreal, Canada and Clinical Professor, Department of Pediatrics, Université de Montréal discuss how advancements in non-invasive prenatal testing (NIPT) for fetal RHD are transforming targeted antenatal prophylaxis with RhIG.
March 2025—Like an inspired Adam in the Garden of Eden, molecular experts have been busy with the naming process as it applies to liquid biopsy. It’s lost to the myths of time whether Adam revised his nomenclature, but pathologists and other experts are eager to identify new assays as they push this field forward, from circulating cell-free DNA to circulating tumor DNA to circulating tumor RNA. Soon another assay, one that combines ctDNA and ctRNA, could begin to make its mark as well, says Keyur P. Patel, MD, PhD, medical director of the molecular diagnostics laboratory, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center. He and his colleagues plan to launch an assay to look for circulating total nucleic acid. “DNA plus RNA equals TNA—that’s the mathematical equation,” jokes Dr. Patel, who is also professor, Department of Hematopathology, Division of Pathology and Laboratory Medicine. And like that first zookeeper, there’s even an actual beast for experts to name.
March 2025—Theresa Kinard, MD, knew little about phosphatidylethanol (PEth), a blood-based biomarker of alcohol use, when she noticed that patients who adamantly denied drinking were testing positive in their liver pretransplant evaluations.
March 2025—The Ventana CLDN18 (43-14A) RxDx Assay, the companion diagnostic for zolbetuximab, detects the claudin 18 protein in formalin-fixed, paraffin-embedded gastric adenocarcinoma including gastroesophageal junction tissue specimens. Gastric intestinal metaplasia can be used as a positive tissue control and system level control and should display weak to moderate membrane staining.
March 2025—For clinical pathology practice, generative artificial intelligence can open new efficiencies and opportunities, and the authors of an article published in Archives of Pathology & Laboratory Medicine set out how it can be used and its risks.
March 2025—I’ve worked in the past with employers that were wholly or majority owned by private equity firms, and the ethos is conspicuously different from that in which ownership is by medical professionals (either MD or MHA), in that it’s all about the bottom line. We can all acknowledge that efficiencies are necessary in American health care, but the core of its ethos must never be questioned; it’s ultimately all about the patient. A situation has arisen in my home state of Connecticut that should alarm anyone interested in health care—the decimation of three fine hospitals by private equity mismanagement, a history that reads sadly like a forensic investigation.
